Nanexa AB (DE:40M)

FRANKFURT:40M

40M

Nanexa AB

RESEARCH TOOLSreports

Want to see DE:40M full AI Analyst Report?

Nanexa AB (40M) Price & Analysis

0 Followers

40M Stock Chart & Stats

€0.25

>-€0.01(-2.14%)

At close: Jan 08 4:00 PM EST

€0.25

>-€0.01(-2.14%)

Day’s Range― - ―

52-Week Range€0.11 - €0.43

Previous CloseN/A

Volume0.00

Average Volume (3M)6.00

Market Cap

€50.73M

Enterprise Value€544.31M

Total Cash (Recent Filing)€44.57M

Total Debt (Recent Filing)€1.12M

Price to Earnings (P/E)11.0

Beta0.70

Next Earnings

Aug 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding164,585,050

10 Day Avg. Volume20

30 Day Avg. Volume6

Financial Highlights & Ratios

PEG Ratio1.02

Price to Book (P/B)6.83

Price to Sales (P/S)19.19

P/FCF Ratio-26.47

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)€10.36M

Bulls Say, Bears Say

Bulls Say

Proprietary Platform (PharmaShell)A durable competitive asset: PharmaShell's ability to convert existing drugs into long-acting injectables creates recurring licensing and royalty opportunities. Platform scope across therapeutic areas improves addressable market, partner appeal, and prospects for repeated deal flow over years.

Rapid Revenue AccelerationSustained top-line acceleration off a low base signals improving commercial traction and validation of development programs or collaborations. Over 2–6 months this momentum supports higher probability of milestone income and demonstrates the model can scale beyond early R&D revenues.

Conservative Balance Sheet LeverageLow financial leverage and a sizable equity base give the company resilience to fund ongoing development without acute insolvency risk. This structural strength provides optionality for partnerships, non-dilutive financing, or staged investment as programs progress toward milestones.

Bears Say

Persistent Cash BurnContinued negative operating and free cash flow is a structural constraint that requires recurring external funding or partner milestone receipts. Over months this elevates dilution and execution risk, potentially forcing concessionary licensing terms or slowed program timelines if funding gaps emerge.

Negative Profitability And ROEOngoing losses and negative ROE indicate the company has not yet converted revenue into sustainable profits. If profitability does not improve structurally, continued erosion of shareholder value and reliance on external capital will persist, limiting strategic flexibility and long-term returns.

Partner-dependent Commercial Model & Small TeamBusiness relies on third-party partnerships to realize value, which lengthens revenue timelines and concentrates execution risk. A very small employee base limits internal commercialization and scale-up capability, making successful partner selection and contract terms critical to durable cash generation.

Nanexa AB News

Nanexa AB’s Phase 1 Study on NEX-22A: A Potential Game-Changer for Diabetes Treatment?

Nanexa AB (($DE:40M)) announced an update on their ongoing clinical study. Study Overview: The recent clinical study by...

7M ago

40M

40M FAQ

What was Nanexa AB’s price range in the past 12 months?

Nanexa AB lowest stock price was €0.10 and its highest was €0.43 in the past 12 months.

What is Nanexa AB’s market cap?

Nanexa AB’s market cap is €50.73M.

When is Nanexa AB’s upcoming earnings report date?

Nanexa AB’s upcoming earnings report date is Aug 14, 2026 which is in 105 days.

How were Nanexa AB’s earnings last quarter?

Currently, no data Available

Is Nanexa AB overvalued?

According to Wall Street analysts Nanexa AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nanexa AB pay dividends?

Nanexa AB does not currently pay dividends.

What is Nanexa AB’s EPS estimate?

Nanexa AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nanexa AB have?

Nanexa AB has 164,585,050 shares outstanding.

What happened to Nanexa AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nanexa AB?

Currently, no hedge funds are holding shares in DE:40M

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nanexa AB

Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.